Table 1 Baseline characteristics of patients in two groups
NT-RFA | C-RFA | P value | |
|---|---|---|---|
n | 46 | 84 | |
Age, years | 52.0 (43.0–58.0) | 51.0 (45.0–59.0) | 0.826 |
Gender, female | 4 (8.7%) | 6 (7.2%) | 0.742* |
BMI, kg/m2 | 23.9 (21.9–26.4) | 23.6 (21.3–25.8) | 0.622 |
Etiology | 0.212* | ||
HBV | 44 (95.7%) | 74 (88.1%) | |
Others | 2 (4.3%) | 10 (11.9%) | |
Cirrhotic basis | 0.124 | ||
Compensated | 32 (69.6%) | 69 (82.1%) | |
Uncompensated | 14 (30.4%) | 15 (17.9%) | |
SLV, cm3 | 1405.0 (1341.0–1484.0) | 1393.0 (1338.0–1454.0) | 0.341 |
Child-Pugh | 0.326* | ||
A | 44 (95.7%) | 75 (89.3%) | |
B | 2 (4.3%) | 9 (10.7%) | |
Decompensated complications | 0.102 | ||
Bleeding varices | 5 (10.9%) | 2 (2.4%) | |
Hepato-renal syndrome | 1 (2.2%) | 0 (0) | |
Hepatic encephalopathy | 2 (4.3%) | 1 (1.2%) | |
Ascites | 6 (13.0%) | 12 (14.3%) | |
Tumor size, mm | 19.0 (15.0–22.0) | 21.0 (16.0–26.0) | 0.048 |
Near major vessels | 12 (26.1%) | 27 (32.1%) | 0.551 |
Lab tests | |||
ALT, IU/l | 30.5 (21.1–47.5) | 31.6 (23.6–47.5) | 0.450 |
TBIL, μmol/L | 18.8 (14.6–23.2) | 16.9 (13.9–23.1) | 0.301 |
ALP, IU/L | 107.0 (82.8–124.5) | 90.0 (77.0–112.0) | 0.075 |
TBA, μmol/L | 5.7 (2.3–13.2) | 7.6 (2.9–16.2) | 0.270 |
PT, sec | 11.9 (11.4–12.5) | 12.0 (11.3–12.9) | 0.327 |
Alb, g/L | 44.7 (39.8–46.7) | 44.8 (40.1–47.4) | 0.634 |
PLT, 10^9/L | 116.0 (88.0–163.3) | 118.5 (78.5–147.5) | 0.376 |
AFP, ng/ml | 27.3 (4.4–224.6) | 13.0 (3.3–105.8) | 0.102 |